卵巣がんの世界市場レポート 2025年

卵巣がん市場規模は、今後数年で飛躍的な成長が見込まれます。2029年にはCAGR18.5％で86億1,000万米ドルに成長します。予測期間の成長は、標的療法や個別化医療に関する調査の増加、高齢者人口の増加、ヘルスケア意識の高まり、卵巣がんの有病率の増加、医療費の増加に起因しています。予測期間における主な動向としては、革新的な治療法、放射線療法の進歩、ヘルスケアインフラの強化、技術の進歩、新薬の採用などが挙げられます。

女性人口の増加が卵巣がん市場の拡大を牽引すると予測されています。女性人口とは、ある時点で特定の地域または世界に居住する女性の総数を指します。この増加は、平均寿命の延長、ヘルスケアの向上、人口動態の変化といった要因の影響を受けています。卵巣がん手術、化学療法、分子標的治療、免疫療法などの治療は、がん細胞を除去し、病気の進行を遅らせ、症状を緩和し、生存率を向上させることで女性人口を支えています。これらの治療は、最終的には生活の質を高め、長期的により良い結果をもたらす希望を与えます。例えば、米国の政府機関である国勢調査局によると、2022年7月現在、米国の女性人口は約1億6,800万人と推定され、その中には85歳以上の女性が約190万人含まれています。さらに、英国の金融サービス会社CEIC Dataが2022年12月に発表した報告書によると、15～64歳の女性人口は2022年には295万1,856人に達し、2021年の294万645人から増加しました。その結果、女性人口の増加が卵巣がん市場の成長に寄与しています。

卵巣がん市場の企業は、複雑な医療データ分析の精度を高めるために、AIプラットフォームなどの先進的なソリューションを優先しています。卵巣がんのAIプラットフォームとは、人工知能（AI）や機械学習（ML）を活用して卵巣がんケアのさまざまな側面を改善する技術主導型のシステムです。これらのプラットフォームは、医療画像、ゲノムデータ、電子カルテ（EHR）、リアルタイム分析を統合し、早期発見、診断、個別化治療計画、患者モニタリングをサポートします。例えば2024年2月、AIIMSデリーはインドのCDACプネと共同で、乳がんや卵巣がんの早期発見のためのAI搭載プラットフォームiOncology.aiを導入しました。このプラットフォームは、ディープラーニングモデルを採用し、放射線画像や病理組織画像を高い精度で解析することで、早期診断と生存率の向上を目指しています。すでに複数の病院に導入されているiOncology.aiは、ヘルスケアシステムと統合してリスク評価を行い、マンモグラフィを推奨し、特に地方の女性に恩恵をもたらします。この取り組みは、ヘルスケアにAIを取り入れ、医療機関の負担を軽減するための幅広い取り組みの一環です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界卵巣がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の卵巣がん市場：成長率分析
• 世界の卵巣がん市場の実績：規模と成長, 2019-2024
• 世界の卵巣がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界卵巣がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の卵巣がん市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 上皮性卵巣腫瘍
• 卵巣胚細胞腫瘍
• 卵巣間質腫瘍
• 原発性腹膜がん
• 世界の卵巣がん市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 標的療法
• 放射線治療
• 免疫療法
• ホルモン療法
• 手術
• 世界の卵巣がん市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の卵巣がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 診断センター
• ドラッグストア
• オンライン薬局
• その他のエンドユーザー
• 世界の卵巣がん市場上皮性卵巣腫瘍の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 漿液性がん
• 粘液がん
• 類内膜がん
• 明細胞がん
• ブレンナー腫瘍
• 世界の卵巣がん市場卵巣胚細胞腫瘍の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 未分化胚細胞腫
• 奇形腫
• 卵黄嚢腫瘍
• 胎児性がん
• 絨毛がん
• 世界の卵巣がん市場卵巣間質腫瘍の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 顆粒膜細胞腫瘍
• テコマス
• セルトリ・ライディッヒ細胞腫瘍
• 世界の卵巣がん市場原発性腹膜がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高悪性度漿液性がん
• 低悪性度漿液性がん

第7章 地域別・国別分析

• 世界の卵巣がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の卵巣がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 卵巣がん市場：競合情勢
• 卵巣がん市場：企業プロファイル
  • Pfizer Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer Aktiengesellschaft
• Sanofi S.A.
• AstraZeneca PLC
• Abbott Laboratories
• GlaxoSmithKline plc
• Eli Lilly and Company
• Boehringer Ingelheim GmbH
• Bausch Health Companies Inc.
• Bristol-Myers Squibb Company
• Sun Pharmaceutical Industries Limited
• Cipla Limited
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Novogen Limited
• Oasmia Pharmaceutical AB

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 卵巣がん市場2029：新たな機会を提供する国
• 卵巣がん市場2029：新たな機会を提供するセグメント
• 卵巣がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs (ova) and hormones such as estrogen and progesterone. It can originate in different parts of the ovaries, including the surface epithelium, germ cells, or stroma.

The primary types of ovarian cancer include epithelial ovarian tumors, ovarian germ cell tumors, ovarian stromal tumors, and primary peritoneal carcinoma. Epithelial ovarian tumors arise from the epithelial cells that form the outer lining of the ovaries. Treatment options include chemotherapy, targeted therapy, radiation therapy, immunotherapy, hormonal therapy, and surgery. These treatments are administered through various routes, such as oral, parenteral, and other methods, and are utilized by different end-users, including hospitals, diagnostic centers, drug stores, online pharmacies, and others.

The ovarian cancer market research report is one of a series of new reports from The Business Research Company that provides ovarian cancer market statistics, including the ovarian cancer industry global market size, regional shares, competitors with the ovarian cancer market share, detailed ovarian cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the ovarian cancer industry. This ovarian cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ovarian cancer market size has grown exponentially in recent years. It will grow from $3.67 billion in 2024 to $4.36 billion in 2025 at a compound annual growth rate (CAGR) of 18.9%. The growth during the historic period can be attributed to the rising elderly population, the increasing incidence of ovarian cancer cases, the growing prevalence of ovarian cancer, the expansion of government initiatives, and the rise in healthcare spending.

The ovarian cancer market size is expected to see exponential growth in the next few years. It will grow to $8.61 billion in 2029 at a compound annual growth rate (CAGR) of 18.5%. The growth in the forecast period can be attributed to increased research on targeted therapies and personalized medicine, a growing geriatric population, rising healthcare awareness, the increasing prevalence of ovarian cancer, and rising healthcare expenditures. Major trends in the forecast period include innovative therapies, advancements in radiation therapy, enhanced healthcare infrastructure, technological advancements, and the adoption of novel drugs.

The growing female population is anticipated to drive the expansion of the ovarian cancer market. The female population refers to the total number of females residing in a specific region or worldwide at a given time. This increase is influenced by factors such as higher life expectancy, improved healthcare, and demographic changes. Ovarian cancer treatments, including surgery, chemotherapy, targeted therapy, and immunotherapy, support the female population by removing cancerous cells, slowing disease progression, alleviating symptoms, and improving survival rates. These treatments ultimately enhance quality of life and provide hope for better long-term outcomes. For example, according to the Census Bureau, a US-based government agency, as of July 2022, the United States had an estimated female population of approximately 168 million, including about 1.9 million females aged 85 and older. Furthermore, a report published in December 2022 by CEIC Data, a UK-based financial services company, indicated that the number of females aged 15-64 reached 2,951,856 in 2022, up from 2,940,645 in 2021. As a result, the rising female population is contributing to the growth of the ovarian cancer market.

Companies in the ovarian cancer market are prioritizing advanced solutions, such as AI platforms, to enhance the accuracy of complex medical data analysis. An AI platform for ovarian cancer is a technology-driven system that utilizes artificial intelligence (AI) and machine learning (ML) to improve various aspects of ovarian cancer care. These platforms integrate medical imaging, genomic data, electronic health records (EHRs), and real-time analytics to support early detection, diagnosis, personalized treatment planning, and patient monitoring. For example, in February 2024, AIIMS Delhi, in collaboration with CDAC Pune, an India-based organization, introduced iOncology.ai, an AI-powered platform for the early detection of breast and ovarian cancer. This platform employs deep learning models to analyze radiological and histopathological images with high accuracy, aiming to improve early diagnosis and survival rates. Already implemented in multiple hospitals, iOncology.ai integrates with the healthcare system to provide risk assessments and recommend mammograms, particularly benefiting women in rural areas. This initiative is part of a broader effort to incorporate AI into healthcare and alleviate pressure on medical facilities.

In February 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired ImmunoGen Inc. for an undisclosed amount. The acquisition aimed to enhance AbbVie's oncology portfolio by incorporating ImmunoGen's innovative antibody-drug conjugate, ELAHERE, alongside other promising cancer therapies. ImmunoGen Inc. is a US-based biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of ovarian cancer.

Major players in the ovarian cancer market are Pfizer Incorporated, Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Novogen Limited, Oasmia Pharmaceutical AB, Clovis Oncology Inc., Aeterna Zentaris Inc., Allarity Therapeutics Inc., Ellipses Pharma Ltd.

North America was the largest region in the ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ovarian cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ovarian cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ovarian cancer market consists of revenues earned by entities by providing services such as screening and early detection services, diagnostic imaging services, surgical treatment services, clinical trial services, and palliative and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ovarian cancer market also includes sales of taxane-based chemotherapy, surgical treatment devices, radiation therapy equipment, angiogenesis inhibitors, and checkpoint inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ovarian Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ovarian cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ovarian cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ovarian cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Epithelial Ovarian Tumors; Ovarian Germ Cell Tumors; Ovarian Stromal Tumors; Primary Peritoneal Carcinoma
• 2) By Treatment: Chemotherapy; Targeted Therapy; Radiation Therapy; Immunotherapy; Hormonal Therapy; Surgery
• 3) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
• 4) By End-user: Hospitals; Diagnostic Centers; Drug Stores; Online Pharmacies; Other End Users
• Subsegments:
• 1) By Epithelial Ovarian Tumors: Serous Carcinoma; Mucinous Carcinoma; Endometrioid Carcinoma; Clear Cell Carcinoma; Brenner Tumors
• 2) By Ovarian Germ Cell Tumors: Dysgerminoma; Teratoma; Yolk Sac Tumor; Embryonal Carcinoma; Choriocarcinoma
• 3) By Ovarian Stromal Tumors: Granulosa Cell Tumors; Thecomas; Sertoli-Leydig Cell Tumors
• 4) By Primary Peritoneal Carcinoma: High-Grade Serous Carcinoma; Low-Grade Serous Carcinoma
• Companies Mentioned: Pfizer Incorporated; Johnson & Johnson Services Inc.; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ovarian Cancer Market Characteristics

3. Ovarian Cancer Market Trends And Strategies

4. Ovarian Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Ovarian Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ovarian Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ovarian Cancer Market Growth Rate Analysis
• 5.4. Global Ovarian Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ovarian Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ovarian Cancer Total Addressable Market (TAM)

6. Ovarian Cancer Market Segmentation

• 6.1. Global Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epithelial Ovarian Tumors
• Ovarian Germ Cell Tumors
• Ovarian Stromal Tumors
• Primary Peritoneal Carcinoma
• 6.2. Global Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• Radiation Therapy
• Immunotherapy
• Hormonal Therapy
• Surgery
• 6.3. Global Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administrations
• 6.4. Global Ovarian Cancer Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Centers
• Drug Stores
• Online Pharmacies
• Other End Users
• 6.5. Global Ovarian Cancer Market, Sub-Segmentation Of Epithelial Ovarian Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Serous Carcinoma
• Mucinous Carcinoma
• Endometrioid Carcinoma
• Clear Cell Carcinoma
• Brenner Tumors
• 6.6. Global Ovarian Cancer Market, Sub-Segmentation Of Ovarian Germ Cell Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dysgerminoma
• Teratoma
• Yolk Sac Tumor
• Embryonal Carcinoma
• Choriocarcinoma
• 6.7. Global Ovarian Cancer Market, Sub-Segmentation Of Ovarian Stromal Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Granulosa Cell Tumors
• Thecomas
• Sertoli-Leydig Cell Tumors
• 6.8. Global Ovarian Cancer Market, Sub-Segmentation Of Primary Peritoneal Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• High-Grade Serous Carcinoma
• Low-Grade Serous Carcinoma

7. Ovarian Cancer Market Regional And Country Analysis

• 7.1. Global Ovarian Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ovarian Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ovarian Cancer Market

• 8.1. Asia-Pacific Ovarian Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ovarian Cancer Market

• 9.1. China Ovarian Cancer Market Overview
• 9.2. China Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ovarian Cancer Market

• 10.1. India Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ovarian Cancer Market

• 11.1. Japan Ovarian Cancer Market Overview
• 11.2. Japan Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ovarian Cancer Market

• 12.1. Australia Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ovarian Cancer Market

• 13.1. Indonesia Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ovarian Cancer Market

• 14.1. South Korea Ovarian Cancer Market Overview
• 14.2. South Korea Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ovarian Cancer Market

• 15.1. Western Europe Ovarian Cancer Market Overview
• 15.2. Western Europe Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ovarian Cancer Market

• 16.1. UK Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ovarian Cancer Market

• 17.1. Germany Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ovarian Cancer Market

• 18.1. France Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ovarian Cancer Market

• 19.1. Italy Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ovarian Cancer Market

• 20.1. Spain Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ovarian Cancer Market

• 21.1. Eastern Europe Ovarian Cancer Market Overview
• 21.2. Eastern Europe Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ovarian Cancer Market

• 22.1. Russia Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ovarian Cancer Market

• 23.1. North America Ovarian Cancer Market Overview
• 23.2. North America Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ovarian Cancer Market

• 24.1. USA Ovarian Cancer Market Overview
• 24.2. USA Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ovarian Cancer Market

• 25.1. Canada Ovarian Cancer Market Overview
• 25.2. Canada Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ovarian Cancer Market

• 26.1. South America Ovarian Cancer Market Overview
• 26.2. South America Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ovarian Cancer Market

• 27.1. Brazil Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ovarian Cancer Market

• 28.1. Middle East Ovarian Cancer Market Overview
• 28.2. Middle East Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ovarian Cancer Market

• 29.1. Africa Ovarian Cancer Market Overview
• 29.2. Africa Ovarian Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ovarian Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ovarian Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ovarian Cancer Market Competitive Landscape And Company Profiles

• 30.1. Ovarian Cancer Market Competitive Landscape
• 30.2. Ovarian Cancer Market Company Profiles
  • 30.2.1. Pfizer Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Ovarian Cancer Market Other Major And Innovative Companies

• 31.1. Bayer Aktiengesellschaft
• 31.2. Sanofi S.A.
• 31.3. AstraZeneca PLC
• 31.4. Abbott Laboratories
• 31.5. GlaxoSmithKline plc
• 31.6. Eli Lilly and Company
• 31.7. Boehringer Ingelheim GmbH
• 31.8. Bausch Health Companies Inc.
• 31.9. Bristol-Myers Squibb Company
• 31.10. Sun Pharmaceutical Industries Limited
• 31.11. Cipla Limited
• 31.12. Hikma Pharmaceuticals PLC
• 31.13. Lupin Limited
• 31.14. Novogen Limited
• 31.15. Oasmia Pharmaceutical AB

32. Global Ovarian Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ovarian Cancer Market

34. Recent Developments In The Ovarian Cancer Market

35. Ovarian Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Ovarian Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ovarian Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ovarian Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer